Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions

Clinical Cancer Research

Volumn 5, Issue 3, 1999, Pages 513-520

  Macaulay, Valentine M ^a   O'Byrne, Ken J ^a   Saunders, Mark P ^a   Braybrooke, Jeremy P ^a   Long, Louise ^a   Gleeson, Fergus ^a   Mason, Clare S ^b   Harris, Adrian L ^a   Brown, Peter ^b   Talbot, Denis C ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b British Biotech Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERANCE; DYSPNEA; EXERCISE TOLERANCE; FEMALE; FEVER; FOLLOW UP; HUMAN; INTRAPLEURAL DRUG ADMINISTRATION; MALE; PAIN ASSESSMENT; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; SCORING SYSTEM; SURVIVAL; THORACOCENTESIS; TREATMENT OUTCOME; ULTRASOUND;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COLLAGENASES; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHENYLALANINE; PLEURAL EFFUSION, MALIGNANT; THIOPHENES;

EID: 0033032228     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Miles, D. W., and Knight, R. K. Diagnosis and management of malignant pleural effusion. Cancer Treat. Rev., 19: 151-168, 1993.
2. Anderson, C. B., Philpott, G. W., and Ferguson, T. B. The treatment of malignant pleural effusions. Cancer (Phila.), 33: 916-922, 1974.
3. Sarma, P. R., and Moore, M. R. Approach to the management of pleural effusion in malignancy. South. Med. J., 71: 133-136, 1987.
4. Fentiman, I. S., Rubens, R. D., and Hayward, J. L. A comparison of intracavitary talc and tetracycline for the control of pleural effusions secondary to breast cancer. Eur. J. Cancer Clin. Oncol., 22: 1079-1081, 1986.
5. Aelony, Y., King, R., and Boutin, C. Thorascopic talc poudrage pleurodesis for chronic recurrent pleural effusions. Ann. Intern. Med., 115: 778-782,1991.
6. Hartman, D. L., Gaither, J. M., Kesler, K. A., Mylet, D. M., Brown, J. W., and Mathur, P. N. Comparison of insufflated talc under thorascopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J. Thorac. Cardiovasc. Surg., I05: 743-747, 1993.
7. Evans, T. R. J., Stein, R. C., Pepper, J. R., Gazet, J-C., Ford, H. T., and Coombes, R. C. A randomized prospective trial of surgical against medical tetracycline pleurodesis in the management of malignant pleural effusions secondary to breast cancer. Eur. J. Cancer, 29A: 316-319, 1993.
8. Walker-Renard, P. B., Vaughn, L. M., and Sahn, S. A. Chemical pleurodesis for malignant pleural effusions. Ann. Intern. Med., 120: 56-64, 1994.
9. Stetler-Stevenson, W. G., Hewitt, R., and Corcoran, M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin. Cancer Biol., 7: 147-154, 1996.
10. Docherty, A. J. P., Lyons, A., Smith, B. J., Wright, E. M., Stephens, P. E., and Harris, T. J. R. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature (Lond.), 318: 66-69, 1985.
11. Gomez, D. E., Alonso, D. F., Yoshiji, H., and Thorgeirsson, U. P. Tissue inhibitors of metallo-proteinases - structure, regulation and biological functions. Eur. J. Cell Biol., 74: 111-122, 1997.
12. Mignatti, P., Tsuboi, R., Robbins, E., and Rifkin, D. B. In vitro angiogenesis on the human amniotic membrane: requirement of basic fibroblast growth factor-induced proteinases. J. Cell Biol., 108: 671-682, 1989.
13. Liotta, L. A., and Stetler-Stevenson, W. G. Metalloproteinases and cancer invasion. Semin. Cancer Biol., 1: 99-106, 1990.
14. Basset, P., Bellocq, J. P., Wolf, C., Stoll, I., Hutin, P., Limacher, J. M., Podhajcer, O. L., Chenard, M. P., Rio, M. C., and Chambon P. A novel metalloproteinase gene specifically expressed in stromal cell of breast carcinomas. Nature (Lond.), 348: 699-704, 1990.
15. Brown, P. D., Bloxidge, R. E., Stuart, N. S. A., Gatter, K. C., and Carmichael, J. Correlation between expression of activated 72-kDa gelatinase and tumor spread in non-small cell lung carcinoma. J. Natl. Cancer Inst., 85: 574-578, 1993.
16. Davies, B., Miles, D. W., Happerfield, L. C., Naylor, M. S., Bobrow, L. G., Rubens, R. D., and Balkwill, F. R. Activity of type IV collagenases in benign and malignant breast disease. Br. J. Cancer, 167: 1126-1131, 1993.
17. Newell, K. J., Witty, J. P., Rodgers, W. H., and Martrisian, L. M. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol. Carcinog., 10: 199-206, 1994.
18. Murray, G. I., Duncan, M. E., O'Neil, P., Melvin, W. T., and Fothergill, J. E. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat. Med., 2: 461-462, 1996.
19. Talbot, D. C., and Brown, P. D. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur. J. Cancer, 32A: 2528-2533, 1996.
20. Chirivi, R. G. S., Garofalo, A., Crimmin, M. J., Bawden, L. J., Stoppacciaro, A., Brown, P. D., and Giavazzi, R. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int. J. Cancer, 58: 460-464, 1994.
21. Taraboletti, G., Garofalo, A., Beloti, D., Drudis, T., Borsotti, P., Scanziani, E., Brown, P. D., and Giavazzi, R. Inhibition of angiogenesis and murine hemangioma growth by batimastat. a synthetic inhibitor of matrix metalloproteinases. J. Natl. Cancer Inst., 87: 293-298, 1995.
22. Davies, B., Brown, P. D., East, N., Crimmin, M. J., and Balkwill, F. R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res., 53: 2087-2091, 1993.
23. Eccles, S. A., Box, G. M., Court, W. J., Bone, E. A., Thomas, W., and Brown, P. D. Control of lymphatic and hematogenous metastases of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat. Cancer Res., 56: 2815-2822, 1996.
24. Sledge, G. W., Qulali, M., Goulet, R., Bone, E. A., and Fife, R. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst, 87: 1546-1550, 1995.
25. Low, J. A., Johnson, M. D., Bone, E. A., and Dickson, RB. The matrix metalloproteinase inhibitor batimastat retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin. Cancer Res., 2: 1207-1214, 1996.
26. Watson, S. A., Morris, T. M., Robinson, G., Crimmin, M. J., Brown, P. B., and Hardcastle, J. D. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat in two human colon carcinoma metastasis models. Cancer Res., 55: 3629-3633, 1995.
27. Hurewitz, A. N., Zucker, S., Mancuso, P., Wu, C. L., Dimassimo, B., Lysik, R. M., and Moutsiakis, D. Human pleural effusions are rich in matrix metalloproteinases. Chest, 102: 1808-1814, 1992.
28. Beattie, G. J., Young, H. A., and Smyth, J. F. Phase I study of intraperitoneal metalloproteinase inhibitor batimastat in patients with malignant ascites. Abstract presented at the 8th NCI-EORTC Symposium on New Drug Development, Amsterdam, March 1994.
29. Wojtowicz-Praga, S., Low, J., Marshall, J., Ness, E., Dickson, R., Barter, J., Sale, M., McCann, P., Moore, J., Cole, A., and Hawkins, M. J. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Investig. New Drugs, 14: 193-202, 1996.
30. Parsons, S. L., Watson, S. A., and Steele, R. J. C. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur. J. Surg. Oncol., 23: 526-531, 1997.
31. Moore, J., Churchill, M., McGowan, J., Mason, C., Richards, S., and Galloway, W. A. Analysis of pseudopeptidyl matrix metalloproteinase inhibitors in plasma. In: E. Reid, H. M. Hill, and I. D. Wilson (eds.), Methodological Surveys in Bioanalysis of Drugs, Vol. 24, pp. 89-94. Cambridge, United Kingdom: Royal Society of Chemistry Information Services, 1996.
32. Shah, V. P., Midha, K. K., Dighe, S., McGilveray, I. J., Skelly, J. P., Yacobi, A., Layloff, T., Viswanathan, C. T., Cook, C. E., and McDowall, R. D. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Eur. J. Drug Metab. Pharmacokinet., 16: 249-255, 1991.
33. McGavin, C. R., Artvinli, M., Naoe, H., and McHardy, G. J. R. Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. Br. Med. J., 2: 241-243, 1978.
34. Bowling, A. Measuring Disease. Oxford: OU Press, 1995.
35. Mahler, D. A., and Wells, C. K. Evaluation of clinical methods for rating dyspnoea. Chest, 93: 580-586, 1988.
36. Brown, P. D., and Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumor activity. Ann. Oncol., 6: 967-974, 1995.
37. Nemunaitis, J., Poole, C., Primrose, J., Rosemurgy, A., Malfetano, J., Brown, P., Berrington, A., Cornish, A., Lynch, K., Rasmussen, H., Kerr, D., Cox, D., and Millar, A. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer term studies. Clin. Cancer Res., 4: 1101-1109, 1998.
38. Boasberg, P., Harbaugh, B., Roth, B., Eisenberger, M., Langleben, A., Allen, R., and Rasmussen, H. Marimastat, a novel matrix metalloproteinase inhibitor in patients with hormone-refractory prostate cancer. Proc. Am. Soc. Clin. Oncol., 15: 671, 1996.